CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Increasing unusual option volume: MULN EQNR APLS WEAT CTIC
March 1, 2022 9:53 AM ESTIncreasing unusual option volume: MULN EQNR APLS WEAT CTIC
... MorePre-Open Stock Movers 03/01: (CTIC) (TGT) (DDD) Higher; (GDRX) (VRM) (AMBA) Lower (more...)
March 1, 2022 9:27 AM ESTPre-Open Stock Movers:
CTI BioPharma Corp. (Nasdaq: CTIC) 54% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 Ã-109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the... More
CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
March 1, 2022 7:17 AM ESTCTI BioPharma (NASDAQ: CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO
... MoreStifel Reiterates Buy Rating on CTI BioPharma (CTIC), Expects Stock to Trade Up Substantially on Vonjo Approval
March 1, 2022 6:41 AM ESTStifel analyst Benjamin Burnett reiterated a Buy rating on CTI BioPharma (NASDAQ: CTIC), following approval of the company's Vonjo drug.
The analyst quotes: "We reiterate our Buy rating on CTIC following the approval of Vonjo (pacritinib) for the treatment of myelofibrosis patients with severe thrombocytopenia.... More
CTI BioPharma (CTIC) Granted FDA Accelerated Approval of VONJO
March 1, 2022 6:01 AM ESTCTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.
"Today's approval of VONJO establishes a new standard of... More
